Cervical Screening and Referral Guidelines

Routine Screening and Recall

Women between the ages of 25 and 49 are screened for cervical cancer every three years. If a smear sample is negative for high-risk (HR) human papillomavirus (HPV), the patient is referred back to routine recall according to her age group.

Referral to Colposcopy

If reflex HR HPV testing is positive, the patient is referred to colposcopy for further assessment within six weeks. Women with high-grade dyskaryosis or abnormalities in glandular cells are referred to colposcopy as urgent appointments to be seen within two weeks. Women with borderline or mild dyskaryosis and who are HR HPV positive are referred to colposcopy as routine appointments to be seen within six weeks.

HPV Test of Cure

Women who have undergone treatment for cervical disease are offered an HPV test of cure six months after treatment. If the test is negative for dyskaryosis and HR HPV, the woman is recalled in three years. If the 6-month post-treatment test is negative for dyskaryosis but positive for HR HPV, the woman is re-referred to colposcopy. If there is evidence of high-grade dyskaryosis, the woman is referred back to colposcopy for reassessment.

Recall Frequency

Women aged 25-49 are recalled for routine screening every three years. Women aged 50-64 are recalled every five years.

The menopause is diagnosed retrospectively and occurs 12 months after the last menstrual period. Women who experience menopause before the age of 50 need contraception for at least 2 years after their last menstrual period, while those over 50 require only 1 year of contraception. Therefore, it would be incorrect to assume that this woman does not need contraception because she is protected. Prescribing the COCP for only 12 months would also be inappropriate, especially since she is a smoker over the age of 35. Hormone replacement therapy should not be used as a sole form of contraception, and barrier methods are less effective than other types of contraception. The most appropriate option is the IUS, which can be used for 7 years (off-licence) or 2 years after her last menstrual period and will take her through menopause. This information is based on the FSRH’s guidelines on contraception for women aged over 40 (July 2010).

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. On average, women in the UK experience menopause at the age of 51. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

Postnatal Check: What to Expect from Your GP

After giving birth, it is important to have a postnatal check with your GP to ensure that you are recovering well and to address any concerns you may have. Here are some of the things you can expect during your 6-week postnatal check:

Performing a Smear Test if Delayed Because of Pregnancy
If you were due for a routine smear test during pregnancy, it will be deferred until at least three months post-delivery. This is to avoid misinterpreting cell changes that occur during pregnancy and to identify any precancerous changes in the cells of the cervix.

Assessment of Mood
Your GP will assess your mood and any psychological disturbance you may be experiencing. This is an opportunity to screen for postnatal depression and identify any need for additional support.

Assessing Surgical Wound Healing and/or the Perineum if Required
Depending on the mode of delivery, your GP will assess the healing of any surgical wounds or perineal tears. They will also check for signs of infection or abnormal healing.

Blood Pressure Reading
Your GP will perform a blood pressure reading, especially if you had hypertension during pregnancy. Urinalysis may also be performed if you had pre-eclampsia or signs of a urinary tract infection.

Discussion of Contraceptive Options
Your GP will discuss family planning and the need for additional contraception, as required. This is important to prevent unintended pregnancies, especially if you are not exclusively breastfeeding.

Overall, the 6-week postnatal check is an important part of your recovery process and ensures that you receive the necessary care and support during this time.

Smouldering myeloma is a stage between monoclonal gammopathy of unknown significance (MGUS) and myeloma. To diagnose this condition, the patient must have a monoclonal protein in the serum of at least 30 g/l and monoclonal plasma cells of at least 10% in bone marrow or tissue biopsy, but no evidence of end-organ damage. Patients with smouldering myeloma should be closely monitored as they are at high risk of developing symptomatic myeloma.

Multiple myeloma is a malignant neoplasm where there is clonal proliferation of plasma cells in the bone marrow, leading to the secretion of a monoclonal antibody and light immunoglobulin chains that cause organ damage. Patients with multiple myeloma present with various symptoms, including lethargy, bone pain, pathological fractures, renal impairment, amyloidosis, and pancytopenia due to marrow infiltration. To diagnose multiple myeloma, the patient must have a monoclonal antibody in serum and/or urine, clonal plasma cells of at least 10% on bone marrow biopsy, and evidence of end-organ damage.

MGUS is a condition where low levels of paraprotein are detected in the blood, but they are not causing clinically significant symptoms or end-organ damage. To diagnose MGUS, the patient must have a monoclonal protein in the serum of less than or equal to 30 g/l, monoclonal plasma cells of less than or equal to 10% in bone marrow or tissue biopsy, and no evidence of end-organ damage.

Non-secretory myeloma is a rare variant of multiple myeloma where the bone marrow findings and end-organ damage are similar to myeloma, but there is no detectable monoclonal protein in the serum or urine. This makes it difficult to diagnose.

Plasma cell leukemia is a rare and aggressive form of multiple myeloma characterized by high levels of plasma cells circulating in the peripheral blood. It can occur as a primary condition or a secondary leukaemic transformation of multiple myeloma.

The T wave on an ECG indicates ventricular repolarisation and is typically positive in all leads except AvR and V1. Abnormal T wave findings may suggest strain, bundle branch block, ischaemia/infarction, hyperkalaemia, Prinzmetal angina, or early STEMI. The P wave represents atrial depolarisation, while atrial repolarisation is hidden by the QRS complex. The PR interval is determined by the duration of conduction delay through the atrioventricular node. Finally, the QRS complex indicates ventricular depolarisation.

It is recommended to wait until the lady reaches 36 weeks of pregnancy to check if the baby has changed position, as she is currently only 30 weeks pregnant. For nulliparous women, such as the lady in this case, ECV should be provided at 36 weeks if the baby remains in the breech position. However, if the lady had previous pregnancies, ECV would be offered at 37 weeks.

Breech presentation occurs when the caudal end of the fetus is in the lower segment, and it is more common at 28 weeks than near term. Risk factors include uterine malformations, placenta praevia, and fetal abnormalities. Management options include spontaneous turning, external cephalic version (ECV), planned caesarean section, or vaginal delivery. The RCOG recommends informing women that planned caesarean section reduces perinatal mortality and early neonatal morbidity, but there is no evidence that the long-term health of babies is influenced by how they are born. ECV is contraindicated in certain cases, such as where caesarean delivery is required or there is an abnormal cardiotocography.

The patient’s symptoms suggest retinal detachment, which is characterized by a painless loss of vision over several hours and the presence of flashes and floaters. Acute closed-angle glaucoma, optic neuritis, diabetic retinopathy, and central retinal artery occlusion are less likely causes as they do not fit the patient’s presentation or symptoms.

Sudden loss of vision can be a scary symptom for patients, as it may indicate a serious issue or only be temporary. Transient monocular visual loss (TMVL) is a term used to describe a sudden, brief loss of vision that lasts less than 24 hours. The most common causes of sudden, painless loss of vision include ischaemic/vascular issues (such as thrombosis, embolism, and temporal arthritis), vitreous haemorrhage, retinal detachment, and retinal migraine.

Ischaemic/vascular issues, also known as ‘amaurosis fugax’, have a wide range of potential causes, including large artery disease, small artery occlusive disease, venous disease, and hypoperfusion. Altitudinal field defects are often seen, and ischaemic optic neuropathy can occur due to occlusion of the short posterior ciliary arteries. Central retinal vein occlusion is more common than arterial occlusion and can be caused by glaucoma, polycythaemia, or hypertension. Central retinal artery occlusion is typically caused by thromboembolism or arthritis and may present with an afferent pupillary defect and a ‘cherry red’ spot on a pale retina.

Vitreous haemorrhage can be caused by diabetes, bleeding disorders, or anticoagulants and may present with sudden visual loss and dark spots. Retinal detachment may be preceded by flashes of light or floaters, which are also common in posterior vitreous detachment. Differentiating between posterior vitreous detachment, retinal detachment, and vitreous haemorrhage can be challenging, but each has distinct features such as photopsia and floaters for posterior vitreous detachment, a dense shadow that progresses towards central vision for retinal detachment, and large bleeds causing sudden visual loss for vitreous haemorrhage.

Regulation of PTH secretion

Parathyroid hormone (PTH) secretion is regulated by various factors. One of these factors is the concentration of calcium in the plasma. When the calcium concentration is high, PTH synthesis and secretion are suppressed. On the other hand, an increase in serum phosphate stimulates PTH secretion. Another factor that affects PTH secretion is the extracellular free calcium level. When the level of extracellular free calcium rises, it stimulates a parathyroid membrane-bound calcium receptor, which inhibits PTH secretion. Therefore, the regulation of PTH secretion is a complex process that involves multiple factors, including calcium and phosphate levels in the blood. Proper regulation of PTH secretion is essential for maintaining calcium and phosphate homeostasis in the body.

Management of Uterine Hyperstimulation Syndrome and Suspicious CTG in Labor

Uterine hyperstimulation syndrome can lead to a suspicious CTG, which requires prompt management to prevent fetal distress. If the patient presents with uterine hyperstimulation syndrome caused by oxytocin infusion, the first step is to reduce the infusion rate and review the CTG in half an hour. If the CTG shows acute bradycardia or prolonged deceleration for more than three minutes, an emergency Caesarean section should be performed if the patient’s cervix is not fully dilated. Instrumental delivery, in the form of forceps or ventouse, is only indicated under certain circumstances, and the patient must be fully dilated. Increasing the oxytocin infusion rate should be avoided as it exacerbates the symptoms of uterine hyperstimulation. When the CTG is normal, no action is required. Early decelerations occur with uterine contractions and are associated with compression of the fetal head during contraction, leading to vagal nerve stimulation and slowing of the fetal heart rate.

Antenatal corticosteroids should be given in cases of preterm prelabour rupture of membranes to reduce the risk of respiratory distress syndrome in the neonate. IM corticosteroids are the appropriate form of administration for this purpose. Cervical cerclage is not recommended in this scenario as it is contraindicated in cases of preterm prelabour rupture of membranes. Expectant management is also not the best option as it increases the risk of intraamniotic infection. Indomethacin tocolysis is not recommended as it can cause complications such as ductus arteriosus closure and oligohydramnios. Nifedipine is the preferred medication for delaying labour in this scenario.

Preterm prelabour rupture of the membranes (PPROM) is a condition that occurs in approximately 2% of pregnancies, but it is responsible for around 40% of preterm deliveries. This condition can lead to various complications, including prematurity, infection, and pulmonary hypoplasia in the fetus, as well as chorioamnionitis in the mother. To confirm PPROM, a sterile speculum examination should be performed to check for pooling of amniotic fluid in the posterior vaginal vault. However, digital examination should be avoided due to the risk of infection. If pooling of fluid is not observed, testing the fluid for placental alpha microglobulin-1 protein (PAMG-1) or insulin-like growth factor binding protein-1 is recommended. Ultrasound may also be useful to show oligohydramnios.

The management of PPROM involves admission and regular observations to ensure that chorioamnionitis is not developing. Oral erythromycin should be given for ten days, and antenatal corticosteroids should be administered to reduce the risk of respiratory distress syndrome. Delivery should be considered at 34 weeks of gestation, but there is a trade-off between an increased risk of maternal chorioamnionitis and a decreased risk of respiratory distress syndrome as the pregnancy progresses. PPROM is a serious condition that requires prompt diagnosis and management to minimize the risk of complications for both the mother and the fetus.